UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy

The Journal of urology, 2014-06, Vol.191 (6), p.1743-1748

2014

Volltextzugriff (PDF)

Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

The Prostate, 2013-01, Vol.73 (1), p.48-53

2013

Volltextzugriff (PDF)

Evaluation of Educational Feedback in Urology Training: A Survey-Based Assessment of Trainees and Program Directors

Curēus (Palo Alto, CA), 2024-01

2024

Volltextzugriff (PDF)

Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer

Cancers, 2022-05, Vol.14 (11), p.2704

2022

Volltextzugriff (PDF)

LBA02-10 UROLOGISTS' PERFORMANCE IN MERIT BASED INCENTIVE PAYMENT SYSTEM: HOW YOU REPORT MATTERS

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

Optilume drug‐coated balloon for anterior urethral stricture: 2‐year results of the ROBUST III trial

BJUI compass, 2024-03, Vol.5 (3), p.366-373

2024

Volltextzugriff (PDF)

Reduction in Hospital Admissions With the Addition of Prophylactic Intramuscular Ceftriaxone Before Transrectal Ultrasonography–guided Prostate Biopsies

Urology (Ridgewood, N.J.), 2015-03, Vol.85 (3), p.511-516

2015

Volltextzugriff (PDF)

Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer

Research and reports in urology, 2013-01, Vol.5 (default), p.29-37

2013

Volltextzugriff (PDF)

PSA Levels and Mortality in Prostate Cancer Patients

Clinical genitourinary cancer, 2024-10, Vol.22 (5), p.102162, Article 102162

2024

Volltextzugriff (PDF)

PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy

The Prostate, 2015-12, Vol.75 (16), p.1951-1957

2015

Volltextzugriff (PDF)

PD29-09 TRENDS IN MINIMALLY INVASIVE SURGICAL THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA: TREATMENT SUBSTITUTION OR TREATMENT EXPANSION EFFECT BY PROSTATIC URETHRAL LIFT?

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

Sensorimotor polyneuropathy and foot-drop as result of a prostate cancer paraneoplastic syndrome

Research and reports in urology, 2013-01, Vol.5 (default), p.159-162

2013

Volltextzugriff (PDF)

Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer

Critical reviews in therapeutic drug carrier systems, 2023, Vol.40 (4), p.69-100

2023

Volltextzugriff (PDF)

PD13-02 TREATMENT TRENDS OF A LARGE ACTIVE SURVEILLANCE COHORT FOR MEN WITH PROSTATE CANCER

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

MP06-15 THE OPTILUME® DRUG COATED BALLOON FOR RECURRENT ANTERIOR URETHRAL STRICTURES: ROBUST III STUDY 4-YEAR INTERIM RESULTS

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume ® Drug-Coated Balloon for Anterior Urethral Strictures

The Journal of urology, 2022-04, Vol.207 (4), p.866-875

2022

Volltextzugriff (PDF)

MP55-16 COMBINATION OF PRE-BIOPSY EXODX TESTING AND mpMRI IMPROVES PREDICTIVE POWER OF HIGH-GRADE PROSTATE CANCER

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic

Canadian Urological Association journal, 2024-07, Vol.18 (7), p.212

2024

Volltextzugriff (PDF)

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic A survey-based assessment of trainees and program directors

Canadian Urological Association journal, 2024-07, Vol.18 (7), p.E212-E219

2024

Volltextzugriff (PDF)

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic: A survey-based assessment of trainees and program directors

Canadian Urological Association journal, 2024-03, Vol.18 (7)

2024

Volltextzugriff (PDF)

Reply by Authors

The Journal of urology, 2022-04, Vol.207 (4), p.875-875

2022

Volltextzugriff (PDF)

LBA02-03 CAN TURBT BE AVOIDED? PRIMARY CHEMOABLATION WITH A REVERSE THERMAL GEL CONTAINING MITOMYCIN (UGN-102) IN PATIENTS WITH LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(36)
Berichte
(2)

Sprache

Englisch
(38)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy

Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

Evaluation of Educational Feedback in Urology Training: A Survey-Based Assessment of Trainees and Program Directors

Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

LBA02-10 UROLOGISTS' PERFORMANCE IN MERIT BASED INCENTIVE PAYMENT SYSTEM: HOW YOU REPORT MATTERS

Optilume drug‐coated balloon for anterior urethral stricture: 2‐year results of the ROBUST III trial

Reduction in Hospital Admissions With the Addition of Prophylactic Intramuscular Ceftriaxone Before Transrectal Ultrasonography–guided Prostate Biopsies

Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

PSA Levels and Mortality in Prostate Cancer Patients

PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy

PD29-09 TRENDS IN MINIMALLY INVASIVE SURGICAL THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA: TREATMENT SUBSTITUTION OR TREATMENT EXPANSION EFFECT BY PROSTATIC URETHRAL LIFT?

Sensorimotor polyneuropathy and foot-drop as result of a prostate cancer paraneoplastic syndrome

Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer

PD13-02 TREATMENT TRENDS OF A LARGE ACTIVE SURVEILLANCE COHORT FOR MEN WITH PROSTATE CANCER

MP06-15 THE OPTILUME® DRUG COATED BALLOON FOR RECURRENT ANTERIOR URETHRAL STRICTURES: ROBUST III STUDY 4-YEAR INTERIM RESULTS

One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume ® Drug-Coated Balloon for Anterior Urethral Strictures

MP55-16 COMBINATION OF PRE-BIOPSY EXODX TESTING AND mpMRI IMPROVES PREDICTIVE POWER OF HIGH-GRADE PROSTATE CANCER

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic A survey-based assessment of trainees and program directors

Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic: A survey-based assessment of trainees and program directors

Reply by Authors

PD43-02 PRIMARY CHEMOABLATION OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER USING UGN-102, A MITOMYCIN-CONTAINING REVERSE THERMAL GEL (OPTIMA II): A PHASE 2b, OPEN-LABEL, SINGLE-ARM TRIAL

LBA02-03 CAN TURBT BE AVOIDED? PRIMARY CHEMOABLATION WITH A REVERSE THERMAL GEL CONTAINING MITOMYCIN (UGN-102) IN PATIENTS WITH LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER

Suchergebnisse filtern